Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition

Yu Chang, Xiaoju Wang, Jianzhang Yang, Jean Ching-Yi Tien, Rahul Mannan, Gabriel Cruz, Yuping Zhang, Josh N. Vo, Brian Magnuson, Somnath Mahapatra,

Cell Reports Medicine · 2024 · 18 citations · 32 references

DOIFull text

Open access

Concepts

Abstract

Cyclin-dependent kinases 12/13 play pivotal roles in orchestrating transcription elongation, DNA damage response, and maintenance of genomic stability. Biallelic CDK12 loss has been documented in various malignancies. Here, we develop a selective CDK12/13 PROTAC degrader, YJ9069, which effectively inhibits proliferation in subsets of prostate cancer cells preferentially over benign immortalized cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. In vivo , YJ9069 significantly suppresses prostate tumor growth. Modifications of YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206, which exhibits comparable efficacy with significantly less toxicity. To identify pathways synthetically lethal upon CDK12/13 degradation, phosphorylation pathway arrays were performed using cell lines treated with YJ1206. Interestingly, degradation or genetic knockdown of CDK12/13 led to activation of the AKT pathway. Targeting CDK12/13 for degradation, in conjunction with inhibiting the AKT pathway, resulted in a synthetic lethal effect in preclinical prostate cancer models. • Development of an orally bioavailable CDK12/13 degrader (YJ1206) • YJ1206 exhibits minimal adverse effects in immune-competent mice • YJ1206 is efficacious in preclinical models of advanced prostate cancer • YJ1206 induces synthetic lethality in conjunction with AKT pathway inhibition Chang et al. develop YJ1206, an orally bioavailable degrader that exhibits high specificity in degrading CDK12/13 and demonstrates robust anti-tumor activity in vivo . The degradation of CDK12/13 leads to activation of the AKT pathway. YJ1206 in combination with AKT inhibitors achieves a striking synthetic lethal effect in prostate cancer models.

References

32